Pharmacology, Toxicology and Pharmaceutical Science
Active Metabolite
18%
Adverse Event
32%
Afimoxifene
18%
Atezolizumab
70%
Biological Marker
27%
Biosimilar Agent
18%
Breast Cancer
98%
Chemotherapy
32%
Clinical Trial
86%
Clopidogrel
21%
Colorectal Carcinoma
27%
Combination Therapy
43%
Comorbidity
16%
Congestive Heart Failure
45%
Cyclophosphamide
18%
CYP2C19
21%
CYP3A4
18%
Cytochrome P450
22%
Drug Interaction
19%
Epidermal Growth Factor Receptor
36%
Glucuronosyltransferase
65%
Glycosyltransferase
36%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
18%
Immune Checkpoint Inhibitor
36%
Irinotecan
21%
Lapatinib
21%
Lung Cancer
18%
Malignant Neoplasm
84%
Medicinal Plant
22%
Metastatic Colorectal Cancer
36%
microRNA
18%
Monoclonal Antibody
36%
Mortality Rate
18%
Multiple Myeloma
18%
Neoplasm
43%
Non Small Cell Lung Cancer
45%
Non-Steroidal Anti-Inflammatory Drug
20%
Obesity
19%
Overall Survival
84%
Pharmacogenetics
22%
Pharmacogenomics
47%
Phosphotransferase Inhibitor
30%
Progression Free Survival
45%
Proton Pump Inhibitor
28%
Randomized Controlled Trial
56%
Receptor
18%
Sorafenib
18%
Trastuzumab Emtansine
21%
Uridine Diphosphate
45%
Vancomycin
45%
Medicine and Dentistry
Adverse Event
16%
Androgen
13%
Anti-Epidermal Growth Factor Receptor
18%
Atezolizumab
57%
Biosimilar
18%
Breast Cancer
48%
Cancer
16%
Cancer Cell
34%
Chemoimmunotherapy
18%
Clinical Study
15%
Clinical Trial
76%
Clinician
15%
Combination Therapy
29%
Comorbidity
16%
Complementary Medicine
18%
Congestive Heart Failure
36%
Disease
18%
Drug Resistance
12%
Epidermal Growth Factor Receptor
19%
Exemestane
12%
Glucuronosyltransferase
20%
Hazard Ratio
12%
Health Care
12%
Immune Checkpoint Inhibitor
25%
Immunity
18%
Immunotherapy
15%
Lung
18%
Lung Cancer
27%
Malignant Neoplasm
32%
Medicine
68%
Meta-Analysis
65%
Metastatic Colorectal Cancer
36%
Monoclonal Antibody
23%
Monoclonal Antibody Therapy
27%
Multiple Myeloma
18%
Neoplasm
43%
Non Small Cell Lung Cancer
32%
Nonsteroid Antiinflammatory Agent
18%
Obesity
16%
Overall Survival
46%
Patient-Reported Outcome
27%
Personalized Medicine
18%
Pharmacogenetic Testing
12%
Pharmacogenomics
18%
Pooled Analysis
29%
Progression Free Survival
28%
Proton-Pump Inhibitor
18%
Randomized Controlled Trial
44%
Subgroup Analysis
18%
Systematic Review
24%
Biochemistry, Genetics and Molecular Biology
Aglycone
10%
Androgen Receptor
12%
Atorvastatin
10%
Binding Domain
13%
Bioinformatics
10%
Cancer Cell
34%
Circular RNA
12%
Clinical Trial
40%
Cochrane Library
9%
Colon
13%
Computer Simulation
23%
CYP2C9
10%
CYP3A4
31%
Cytochrome P450
20%
Drug Therapy
10%
Enzyme
63%
Exon
25%
Gene Expression
12%
Genetic Polymorphism
10%
Glucuronidation
29%
Glucuronosyltransferase
90%
Glycosyltransferase
85%
Immune Checkpoints
18%
Immunity
18%
Intestine Flora
9%
Isoform
15%
Kinase
25%
LNCaP
10%
Medicinal Plant
12%
Medline
10%
Messenger RNA
21%
Metabolic Pathway
79%
MicroRNA
23%
Nuclear Receptor
12%
Overall Survival
33%
Peroxisome Proliferator-Activated Receptor
18%
Pharmacogenetics
12%
Phosphotransferase
25%
Progression Free Survival
9%
Protein Kinase
27%
Proton Pump
18%
Small Molecule
15%
Statin
18%
Transcriptome
14%
UGT1A8
10%
UGT1A@
24%
UGT2B4
10%
UGT2B7
23%
Untranslated Region
19%
Uridine Diphosphate
100%